Drug Trial Radar · NCT05773820
A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
63
Actual
Start
May 5, 2023
Primary completion
Dec 31, 2027
Study completion Jul 31, 2028
Sponsor
- Lead sponsor
- Wigen Biomedicine Technology (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Sponsor GmbH
- First posted
- Mar 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/II study to evaluate the safety and tolerability, DLT(Dose limited toxicity), MTD(Maximum tolerated dose), and RP2D(Recommended phase II dose) of WJB001 capsules in patients with advanced solid tumors, including dose escalation phase, dose expansion phase and cohort expansion phase.The study includes screening, treatment and follow-up periods. In the Dose Escalation phase:Accelerated titration (the first two dose groups) and "BOIN" combination (the subsequent dose group) were used for dose escalation. In the Dose Expansion phase:Based on the previous data, 1 to 2 doses were selected to further evaluate the initial efficacy, safety, tolerability and pharmacokinetic characteristics to confirm RP2D. In the Efficacy Expansion phase:The preliminary plan of Efficacy expansion phase uses the Simon two-stage optimal method to expand 2 to 3 cohorts.
Conditions
- Advanced Solid Tumors
Interventions
WJB001Drug
WJB001 Capsules:160mg(or othe dosages),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies,Every 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1.Dose limited toxicity (DLT)Time frame: 21d
- 2.Adverse event (AE)Time frame: 3 years
- 3.Serious adverse event (SAE)Time frame: 3 years
- 4.Maximum tolerated dose (MTD)Time frame: 2 years
- 5.Recommended phase II dose (RP2D)Time frame: 2 years
- 6.Objective response rate(ORR)Time frame: 3 years
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Tumor Hospital Affiliated to Guangxi Medical University
Nanning, Guangxi, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Fuxin People's Hospital (Fuxin Women and Children's Medical Center)
Fuxin, Liaoning, China
Liaoning Cancer Hospital
Shenyang, Liaoning, China
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
The First Affiliated Hospital of Xi 'an Jiaotong University
Xi’an, Shanxi, China
Henan Cancer Hospital
Henan, Zhenzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.